English

NGM BIOPHARMACEUTICALS INC

EDGAR

NGM Annual report amendment (10-K/A) · filed 2024-04-04

30 filing records in this dataset, filed from 2018-09-28 to 2024-04-04. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

165 thousand USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 4417000 USD Source
Revenue: 4252000 USD Source

Operating margin

-17,977.58%

2023 Q4 · %

Exact inputs and evidence

Operating Income: -151463000 USD Source
Operating Income: -121800000 USD Source
Revenue: 4417000 USD Source
Revenue: 4252000 USD Source

Operating cash flow

-23 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -132202000 USD Source
Operating Cash Flow: -109239000 USD Source

Cash and cash equivalents: 55.8 million USD 2023-12-31 Source
Exact value

55816000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 82.9 million shares 2023-12-31 Source
Exact value

82900000 shares

Reported share-count change

1.22% · 1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

81900000 shares · 2022-12-31· Source
82900000 shares · 2023-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

4.37 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Revenue: 2200000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 1423000 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 582000 USD · 2023-07-01 – 2023-09-30 Source
Revenue: 4417000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 4252000 USD · 2023-01-01 – 2023-09-30 Source

Net income

-142 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Net income: -47647000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -38261000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -28797000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -142375000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -114705000 USD · 2023-01-01 – 2023-09-30 Source

Operating cash flow

-132 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Operating cash flow: -41827000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -82075000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -41827000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -109239000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -82075000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -132202000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -109239000 USD · 2023-01-01 – 2023-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-04-04.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2023-12-31
Operating income: 7 of 11 periods available· newest 2023-12-31
Net income: 7 of 11 periods available· newest 2023-12-31
Operating cash flow: 7 of 11 periods available· newest 2023-12-31
capital expenditure: No compatible figures in this window
Total assets: 6 of 11 periods available· newest 2023-12-31
Total liabilities: 6 of 11 periods available· newest 2023-12-31
Current assets: 6 of 11 periods available· newest 2023-12-31
Current liabilities: 6 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-92%

Prior period

USD 55.33 million

2022-01-01 – 2022-12-31
Current period

USD 4.42 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

4417000 − 55333000 = -50916000 USD

55333000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
4417000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NGM BIOPHARMACEUTICALS INC · 2023-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Year-over-year change in Revenue: -50916000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 4417000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1076894 Filing: 000162828024010232 Input fundies:Revenue: 55333000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1077776 Filing: 000162828024010232
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 20.29 million

Prior period

−USD 162.67 million

2022-01-01 – 2022-12-31
Current period

−USD 142.38 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-142375000 − -162667000 = 20292000 USD

-162667000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-142375000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NGM BIOPHARMACEUTICALS INC · 2023-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Year-over-year change in Net income: 20292000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -142375000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1340712 Filing: 000162828024010232 Input fundies:NetIncome: -162667000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1341376 Filing: 000162828024010232
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 12.24 million

Prior period

−USD 144.44 million

2022-01-01 – 2022-12-31
Current period

−USD 132.2 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-132202000 − -144439000 = 12237000 USD

-144439000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-132202000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NGM BIOPHARMACEUTICALS INC · 2023-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Year-over-year change in Operating cash flow: 12237000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -132202000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1241196 Filing: 000162828024010232 Input fundies:OperatingCashFlow: -144439000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1241849 Filing: 000162828024010232
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 4.42 million 100% of revenue
Operating costs Derived USD 155.88 million 3,529% of revenue
Operating income −USD 151.46 million −3,429% of revenue
Tax, interest and other Derived −USD 9.09 million −206% of revenue
Net income −USD 142.38 million −3,223% of revenue

Cash

Operating cash flow −USD 132.2 million −2,993% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 123% of revenue.
2018 Operating loss: operating costs were 104% of revenue.
2019 Operating loss: operating costs were 148% of revenue.
2020 Operating loss: operating costs were 219% of revenue.
2021 Operating loss: operating costs were 255% of revenue.
2022 Operating loss: operating costs were 400% of revenue.
2023 Operating loss: operating costs were 3,529% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	77141000	94566000 Derived	-17425000	-3266000 Derived	-14159000	Unavailable	Source 2017-01-01 – 2017-12-31: 77141000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -17425000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -14159000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -17413000 USD Inspect Operating Cash Flow Open source
2018 2018-01-01 – 2018-12-31	108665000	112979000 Derived	-4314000	-3821000 Derived	-493000	Unavailable	Source 2018-01-01 – 2018-12-31: 108665000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -4314000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -493000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -7597000 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	103544000	152884000 Derived	-49340000	-6545000 Derived	-42795000	Unavailable	Source 2019-01-01 – 2019-12-31: 103544000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -49340000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -42795000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -41174000 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	87368000	191201000 Derived	-103833000	-1346000 Derived	-102487000	Unavailable	Source 2020-01-01 – 2020-12-31: 87368000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -103833000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -102487000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -83496000 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	77882000	198577000 Derived	-120695000	-360000 Derived	-120335000	Unavailable	Source 2021-01-01 – 2021-12-31: 77882000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -120695000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -120335000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -73229000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	55333000	221582000 Derived	-166249000	-3582000 Derived	-162667000	Unavailable	Source 2022-01-01 – 2022-12-31: 55333000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -166249000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -162667000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -144439000 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	4417000	155880000 Derived	-151463000	-9088000 Derived	-142375000	Unavailable	Source 2023-01-01 – 2023-12-31: 4417000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -151463000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -142375000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -132202000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 4.4M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	77141000	Revenue: 77141000 Open source
20182018-12-31	Revenue	108665000	Revenue: 108665000 Open source
20192019-12-31	Revenue	103544000	Revenue: 103544000 Open source
20202020-12-31	Revenue	87368000	Revenue: 87368000 Open source
20212021-12-31	Revenue	77882000	Revenue: 77882000 Open source
20222022-12-31	Revenue	55333000	Revenue: 55333000 Open source
20232023-12-31	Revenue	4417000	Revenue: 4417000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-92% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 77141000 Open source
20182018-12-31	Year over year	40.9%	Revenue: 108665000 Open source Revenue: 77141000 Open source
20192019-12-31	Year over year	-4.7%	Revenue: 103544000 Open source Revenue: 108665000 Open source
20202020-12-31	Year over year	-15.6%	Revenue: 87368000 Open source Revenue: 103544000 Open source
20212021-12-31	Year over year	-10.9%	Revenue: 77882000 Open source Revenue: 87368000 Open source
20222022-12-31	Year over year	-29%	Revenue: 55333000 Open source Revenue: 77882000 Open source
20232023-12-31	Year over year	-92%	Revenue: 4417000 Open source Revenue: 55333000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,429.1% 2023

Net margin -3,223.3% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-22.6%	Operating Income: -17425000 Open source Revenue: 77141000 Open source
20182018-12-31	Operating margin	-4%	Operating Income: -4314000 Open source Revenue: 108665000 Open source
20192019-12-31	Operating margin	-47.7%	Operating Income: -49340000 Open source Revenue: 103544000 Open source
20202020-12-31	Operating margin	-118.8%	Operating Income: -103833000 Open source Revenue: 87368000 Open source
20212021-12-31	Operating margin	-155%	Operating Income: -120695000 Open source Revenue: 77882000 Open source
20222022-12-31	Operating margin	-300.5%	Operating Income: -166249000 Open source Revenue: 55333000 Open source
20232023-12-31	Operating margin	-3,429.1%	Operating Income: -151463000 Open source Revenue: 4417000 Open source
20172017-12-31	Net margin	-18.4%	Net Income: -14159000 Open source Revenue: 77141000 Open source
20182018-12-31	Net margin	-0.5%	Net Income: -493000 Open source Revenue: 108665000 Open source
20192019-12-31	Net margin	-41.3%	Net Income: -42795000 Open source Revenue: 103544000 Open source
20202020-12-31	Net margin	-117.3%	Net Income: -102487000 Open source Revenue: 87368000 Open source
20212021-12-31	Net margin	-154.5%	Net Income: -120335000 Open source Revenue: 77882000 Open source
20222022-12-31	Net margin	-294%	Net Income: -162667000 Open source Revenue: 55333000 Open source
20232023-12-31	Net margin	-3,223.3%	Net Income: -142375000 Open source Revenue: 4417000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 77141000 Open source Operating Cash Flow: -17413000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 108665000 Open source Operating Cash Flow: -7597000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 103544000 Open source Operating Cash Flow: -41174000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 87368000 Open source Operating Cash Flow: -83496000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 77882000 Open source Operating Cash Flow: -73229000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 55333000 Open source Operating Cash Flow: -144439000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 4417000 Open source Operating Cash Flow: -132202000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -132.2M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-17413000	Operating Cash Flow: -17413000 Open source
20182018-12-31	Operating cash flow	-7597000	Operating Cash Flow: -7597000 Open source
20192019-12-31	Operating cash flow	-41174000	Operating Cash Flow: -41174000 Open source
20202020-12-31	Operating cash flow	-83496000	Operating Cash Flow: -83496000 Open source
20212021-12-31	Operating cash flow	-73229000	Operating Cash Flow: -73229000 Open source
20222022-12-31	Operating cash flow	-144439000	Operating Cash Flow: -144439000 Open source
20232023-12-31	Operating cash flow	-132202000	Operating Cash Flow: -132202000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -17413000 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -7597000 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -41174000 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -83496000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -73229000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -144439000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -132202000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Liabilities / assets	Not reported	No source recorded
20182018-12-31	Liabilities / assets	24.1%	Total Liabilities: 59406000 Open source Total Assets: 246085000 Open source
20192019-12-31	Liabilities / assets	13.1%	Total Liabilities: 49684000 Open source Total Assets: 380403000 Open source
20202020-12-31	Liabilities / assets	14.9%	Total Liabilities: 49000000 Open source Total Assets: 329043000 Open source
20212021-12-31	Liabilities / assets	16.6%	Total Liabilities: 66740000 Open source Total Assets: 402387000 Open source
20222022-12-31	Liabilities / assets	15.6%	Total Liabilities: 47842000 Open source Total Assets: 307402000 Open source
20232023-12-31	Liabilities / assets	12%	Total Liabilities: 20230000 Open source Total Assets: 168868000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.79× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2017-12-31	Current assets / current liabilities	Not reported	No source recorded
20182018-12-31	Current assets / current liabilities	5.17×	Current Assets: 214557000 Open source Current Liabilities: 41486000 Open source
20192019-12-31	Current assets / current liabilities	8.94×	Current Assets: 355248000 Open source Current Liabilities: 39718000 Open source
20202020-12-31	Current assets / current liabilities	7.24×	Current Assets: 308426000 Open source Current Liabilities: 42583000 Open source
20212021-12-31	Current assets / current liabilities	6.18×	Current Assets: 379280000 Open source Current Liabilities: 61355000 Open source
20222022-12-31	Current assets / current liabilities	6.04×	Current Assets: 288859000 Open source Current Liabilities: 47842000 Open source
20232023-12-31	Current assets / current liabilities	7.79×	Current Assets: 156444000 Open source Current Liabilities: 20081000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 14.16 million Exact value Exact value: -14159000 USD 2017-01-01 – 2017-12-31: -14159000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2017-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -14159000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14159000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000156459020011422/ngm-20191231.xml#190447 Filing: 000156459020011422 The citation records this snapshot. The page link may show a newer release later.	−USD 17.41 million Exact value Exact value: -17413000 USD 2017-01-01 – 2017-12-31: -17413000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2017-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -17413000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17413000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000156459020011422/ngm-20191231.xml#226119 Filing: 000156459020011422 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 493,000 Exact value Exact value: -493000 USD 2018-01-01 – 2018-12-31: -493000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2018-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -493000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -493000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000156459021013179/ngm-20201231.xml#177503 Filing: 000156459021013179 The citation records this snapshot. The page link may show a newer release later.	−USD 7.6 million Exact value Exact value: -7597000 USD 2018-01-01 – 2018-12-31: -7597000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2018-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -7597000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7597000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000156459021013179/ngm-20201231.xml#214968 Filing: 000156459021013179 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 42.8 million Exact value Exact value: -42795000 USD 2019-01-01 – 2019-12-31: -42795000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2019-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -42795000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42795000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828022004526/ngm-20211231.htm#1682092 Filing: 000162828022004526 The citation records this snapshot. The page link may show a newer release later.	−USD 41.17 million Exact value Exact value: -41174000 USD 2019-01-01 – 2019-12-31: -41174000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2019-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -41174000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41174000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828022004526/ngm-20211231.htm#1546230 Filing: 000162828022004526 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 102.49 million Exact value Exact value: -102487000 USD 2020-01-01 – 2020-12-31: -102487000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2020-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -102487000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -102487000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828023005569/ngm-20221231.htm#1583122 Filing: 000162828023005569 The citation records this snapshot. The page link may show a newer release later.	−USD 83.5 million Exact value Exact value: -83496000 USD 2020-01-01 – 2020-12-31: -83496000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2020-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -83496000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -83496000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828023005569/ngm-20221231.htm#1463885 Filing: 000162828023005569 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 120.34 million Exact value Exact value: -120335000 USD 2021-01-01 – 2021-12-31: -120335000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2021-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -120335000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -120335000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1342040 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	−USD 73.23 million Exact value Exact value: -73229000 USD 2021-01-01 – 2021-12-31: -73229000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2021-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -73229000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73229000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1242502 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 162.67 million Exact value Exact value: -162667000 USD 2022-01-01 – 2022-12-31: -162667000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2022-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -162667000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -162667000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1341376 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	−USD 144.44 million Exact value Exact value: -144439000 USD 2022-01-01 – 2022-12-31: -144439000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2022-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -144439000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -144439000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1241849 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 142.38 million Exact value Exact value: -142375000 USD 2023-01-01 – 2023-12-31: -142375000 USD Inspect Net Income Open source Share or cite Citation for Net Income · NGM BIOPHARMACEUTICALS INC · 2023-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Net Income: -142375000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -142375000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1340712 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	−USD 132.2 million Exact value Exact value: -132202000 USD 2023-01-01 – 2023-12-31: -132202000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NGM BIOPHARMACEUTICALS INC · 2023-12-31 NGM BIOPHARMACEUTICALS INC (edgar:1426332) Operating Cash Flow: -132202000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:39Z Snapshot: cc543b72d43332eb3660afe07df8d1d07afcaf675142fd6a9af09b485032d9b7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1426332/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -132202000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm#1241196 Filing: 000162828024010232 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,436 latest values · 1,436 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001426332, 1426332, NGM, edgar:1426332

Also known as NGM BIOPHARMACEUTICALS INC, NGM BIOPHARMACEUTICALS, INC.

NGM BIOPHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation